Navigation Links
Diamyd(R) Study Published in Prestigious New England Journal of Medicine
Date:10/9/2008

duce insulin significantly better than the patients, who received placebo. The best effect was seen in patients, for whom treatment was begun shortly after diagnosis, since those patients still retained a significant amount of the cells that produce insulin. The results indicate that the Diamyd(R) vaccine may also be effective in preventing type 1 diabetes.

About ongoing Phase III studies with Diamyd(R) Type 1:

There are currently two Phase III studies in progress: one in Europe and one in the US. The studies apply to children and adolescents diagnosed with type 1 diabetes within the last three months.

This information is disclosed in accordance with the Securities Markets Act, the Financial Instruments Trading Act or demands made in the exchange rules.

Diamyd Medical is a Swedish biopharmaceutical company focusing on development of pharmaceuticals for treatment of autoimmune diabetes and its complications. The company's most advanced project is the GAD-based drug Diamyd(R) for type 1 diabetes and for which Phase III trials are ongoing in both the US and Europe. Furthermore, the company has initiated clinical studies within chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson's disease.

Diamyd Medical has offices in Sweden and in the US. The share is quoted on the OMX Stockholm Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further information is available on the company's web site: http://www.diamyd.com

For more information, please contact:

Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.),

elisabeth.lindner@diamyd.com ,

Phone: +46-8-661-0026.

For pictures and press material, please contact:

'/>"/>
SOURCE Diamyd Medical AB (publ)
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe
2. Wild Blueberries Take Top Spot in New Antioxidant Research Study
3. National Study Presented at ACG 2008 Confirms New Device Functions Like Rear-View Mirror to Provide Improved View of the Colon
4. Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period
5. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
6. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
7. New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohns Disease According to First-of-its Kind Study
8. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
9. Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study
10. The Childrens Hospital of Philadelphia Announces New Regional Participant in The National Childrens Study
11. Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "China Orthopedic Instrument Industry Report, 2014-2017" ... accelerated aging population and rising proportion of reimbursement for ... been effectively released, with its scale presenting a CAGR ... joint products are three product segments of orthopedic instruments ...
(Date:8/29/2014)... Research and Markets  has announced the addition ... report to their offering. The Central ... the largest segments of pharmaceuticals industry. The numbers of CNS ... therapies were unable to meet the market requirements. There has ... disorder, especially over the past two decades. The market for ...
(Date:8/29/2014)... -- Does your doctor know what you,re smoking?  Chances are, ... to the over 112,000 currently registered patients under ... other roughly 20,300+ active physicians listed with the Colorado Dept ... even though a poll in February 2014 showed 51% of ... it. "With marijuana legalization underway, every doctor ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... , EMERYVILLE, Calif., Nov. 5 Bionovo, Inc. (Nasdaq: ... focused on the unmet needs in women,s health and ... for the three months ended September 30, 2009. , ... 2009, Bionovo successfully completed a public offering and issued ...
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be ... Phoenix, Arizona on Wednesday, November 11, 2009 at 10:00 a.m. ... president of finance and chief financial officer at Amylin Pharmaceuticals, ... of the presentation will be webcast and a recording will ...
Cached Medicine Technology:Bionovo Announces Third Quarter 2009 Highlights and Financial Results 2Bionovo Announces Third Quarter 2009 Highlights and Financial Results 3Bionovo Announces Third Quarter 2009 Highlights and Financial Results 4Bionovo Announces Third Quarter 2009 Highlights and Financial Results 5Bionovo Announces Third Quarter 2009 Highlights and Financial Results 6Bionovo Announces Third Quarter 2009 Highlights and Financial Results 7Bionovo Announces Third Quarter 2009 Highlights and Financial Results 8Bionovo Announces Third Quarter 2009 Highlights and Financial Results 9
(Date:9/1/2014)... Albany, New York (PRWEB) September 01, 2014 ... to store, retrieve, organize and analyze biological and ... comprises of the activity of developing software tools ... is not to be confused with biological computation. ... the better understanding of biology can its related ...
(Date:9/1/2014)... Registration is now open for the 4th Annual ... to be held on Sunday, September 21, 2014. The event ... Meadow in Secaucus, New Jersey. All proceeds from the race ... to restoring a sense of self, restoring the family unit, ... families. , General registration is $30 with special pricing for ...
(Date:9/1/2014)... Daily Gossip reveals in it's review ... that gives members access to thousands of professionally designed ... resource aims to help both people who plan on ... are looking for inspiration in creating one of a ... Now by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 ...
(Date:9/1/2014)... September 01, 2014 Pastor Thompson is an ... at Eagle Village. He is a licensed minister through the ... the past twenty years in New Mexico, Colorado and North ... of marriage this year. He also has two beautiful ... B.S. in Pastoral Ministry from Nazarene Bible College, in Colorado ...
(Date:9/1/2014)... 01, 2014 Psychogenic Non-epileptic Seizures (PNES), ... psychological disorder that can have devastating effects on those ... epileptic seizures however, they are not produced by electrical ... It is estimated that the numbers of persons ... multiple sclerosis. , Dr. Lorna Myers, Director ...
Breaking Medicine News(10 mins):Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2
... key part of health care reform that requires all Americans ... people gaining coverage, but would not dramatically increase the cost ... comes as the U.S. Supreme Court prepares to hear arguments ... key provision of 2010,s Affordable Care Act. According ...
... News) -- Using an autoinjector device to deliver ... effective way to treat status epilepticus, a prolonged type ... report. "This is a very important study for ... French, first vice president of the American Epilepsy Society. ...
... , WEDNESDAY, Feb. 15 (HealthDay News) -- How fast you ... help predict your odds for dementia or stroke later in life, ... can be easily performed in a doctor,s office, noted study author ... and her colleagues tested the walking speed, hand grip strength and ...
... Hospitalization for underage drinking is common in the United States, ... total cost for these hospitalizations is about $755 million per ... found geographic and demographic differences in the incidence of alcohol-related ... Journal of Adolescent Health . Of the ...
... may be receiving the highest exposure to nanoparticles of titanium ... than adults, according to a new study. Published in ACS, ... first broadly based information on amounts of the nanomaterial ... and environmental effects in a wide range of consumer ...
... -- About 27 million Americans aged 50 and older have ... hearing aid, a new study finds. However, many people ... insurance, they don,t receive training in integrating hearing aids into ... part of aging and not a major concern, according to ...
Cached Medicine News:Health News:Ending individual mandate would not dramatically hike insurance prices, study finds 2Health News:Ending individual mandate would not dramatically hike insurance prices, study finds 3Health News:'Autoinjector' Offers Safe, Speedy Care for Life-Threatening Seizures: Study 2Health News:'Autoinjector' Offers Safe, Speedy Care for Life-Threatening Seizures: Study 3Health News:Can Walking Speed, Hand Grip in Middle Age Predict Dementia Risk? 2Health News:Mayo Clinic: Hospitalization of US underage drinkers common, costs $755 million a year 2Health News:Millions of Americans Have Untreated Hearing Loss: Study 2
Large: 22 x 25 mm, 0.9 x 1.0 inches. With holes. For support of the orbital rim following enucleation. Available in methylmethacrylate....
Soft, autoclavable, and without conformer....
Size: Small. 20.50 mm by 22.00 mm. Clear lucite. Supplied sterile....
... x 100 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
Medicine Products: